echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yingli Pharmaceutical's PI3Kδ inhibitor listing application plans to be included in priority review

    Yingli Pharmaceutical's PI3Kδ inhibitor listing application plans to be included in priority review

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Yingli Pharmaceutical’s new drug application for the new generation of PI3Kδ inhibitor linpris tablets has been included in the proposed priority review list.


    It is reported that in February 2021, Hengrui Medicine has reached a cooperation with Yingli Pharmaceutical and obtained the joint development rights and exclusive commercialization rights of the drug in the Greater China region.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.